Skip to content

Smart Catheter: A Novel Biosensor for Early Detection of Catheter Associated Urinary Tract Infection

Smart Catheter: A Novel Biosensor for Early Detection of Catheter Associated Urinary Tract Infection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04315129
Enrollment
100
Registered
2020-03-19
Start date
2018-04-01
Completion date
2021-07-31
Last updated
2021-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-Associated Urinary Tract Infection

Keywords

Biosensor

Brief summary

Urinary Tract Infection (UTI) is the most common hospital acquired infection worldwide, and is most commonly associated with catheterisation of the bladder. Catheter associated urinary tract infection (CAUTI) causes increased hospital costs, increased length of stay and increased mortality. This burden of disease is, in part, mediated by a lack of diagnostic and monitoring modalities for CAUTI. Both traditional and novel UTI diagnostic tests are susceptible to false positives associated with bacterial colonisation, and correlate poorly with clinically meaningful symptomatic CAUTI. As such, the current standard of care is reliant on clinical monitoring, which is susceptible to diagnostic delays, over and under treatment. Imperial College London have developed a wireless biosensor for continuous monitoring of catheter-urine biochemistry. This project aims to validate this biosensor and demonstrate it's potential for preemptive CAUTI diagnosis through continuous urinary biochemical monitoring.

Detailed description

This research project aims to demonstrate that continuous urinary biochemical monitoring using a Smart Catheter biosensor can provide rapid diagnosis of impending catheter associated urinary tract infection (CAUTI). The primary research question will then be: Does the Smart Catheter device reduce the time to diagnosis of CAUTI? This will be accomplished through four studies: The aim of the first study will be to show the reliability and robustness of the Smart Catheter device through the question: Is there any difference between the biochemical measurements from the Smart catheter device and a gold-standard laboratory measurement? The aim of the second and third studies aim to demonstrate the different biochemical profiles of infected and healthy urine by addressing the research question: What is the difference in biochemical concentrations in healthy urine as compared to infected urine? Study 3 will accomplish this by comparing infected human catheter-acquired urine as compared to uninfected human catheter-urine. Study 3 will monitor the changes in biochemical changes in an artifical bladder with artificial urine over time while an infection is induced. The final study will demonstrate the reduced time to diagnosis in a clinical setting by addressing the research question: What is the time difference in diagnosis of CAUTI from the CAUTI as compared to the current standard of clinical monitoring?

Interventions

DIAGNOSTIC_TESTSmart Catheter Biosensor

A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection

Sponsors

Imperial College London
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

The biosensors will monitor for infections. As this is an unverified, experimental diagnosis, this will not be made available to the patient or care provider. similarly this will not be available to the clinical researchers in order to avoid observation bias. While the participants, providers and investigators will all be aware that the participants have an active biosensor, they will be blinded to the output thereof.

Intervention model description

Singlearm blinded study in which biosensor diagnosed infection (experiment) will be compared to clinical diagnosis (control) in a single cohort of surgical patients

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older Subjects expected to undergo catheterisation as part of their clinical care. Signed informed consent is a prerequisite for inclusion in the study.

Exclusion criteria

* Consent to participate not given Known sensitivity to urinary catheters or electronic products Patients undergoing urologic procedures

Design outcomes

Primary

MeasureTime frameDescription
Time difference of diagnosisFrom the time of catheterisation, until 72hours post-removal of catheters.The time difference of biosensor diagnosis of catheter associated UTI as compared to clinical diagnosis (defined as the prescription time of new antimicrobials for suspected UTI)

Secondary

MeasureTime frameDescription
SensitivityFrom the time of catheterisation, until 72hours post-removal of catheters.The proportion of those subjects who went on to develop CAUTI did the Smart Catheter correctly predict would have CAUTI?
SpecificityFrom the time of catheterisation, until 72hours post-removal of catheters.The proportion of those subjects who did not go on to develop CAUTI did the Smart Catheter correctly predict would not have CAUTI.
False Positive RateFrom the time of catheterisation, until 72hours post-removal of catheters.The proportion of those subjects who would not go on to have CAUTI did the Smart Catheter incorrectly predict would have CAUTI?
False Negative RateFrom the time of catheterisation, until 72hours post-removal of catheters.The proportion of those subjects who would go on to have CAUTI did the Smart Catheter incorrectly predict would not have CAUTI?

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026